Machine-Learning-Based Late Fusion on Multi-Omics and Multi-Scale Data for Non-Small-Cell Lung Cancer Diagnosis
Metadata
Show full item recordAuthor
Carrillo Pérez, Francisco; Morales Vega, Juan Carlos; Rojas Ruiz, Ignacio; Herrera Maldonado, Luis JavierEditorial
MDPI
Materia
NSCLC Machine learning Information fusion Deep learning Personalized medicine Artificial neural networks
Date
2022-04-08Referencia bibliográfica
Carrillo-Perez, F... [et al.]. Machine- Learning-Based Late Fusion on Multi-Omics and Multi-Scale Data for Non-Small-Cell Lung Cancer Diagnosis. J. Pers. Med. 2022, 12, 601. [https://doi.org/10.3390/jpm12040601]
Sponsorship
Government of Andalusia RTI2018-101674-B-I00; CV20-64934 P20-00163Abstract
Differentiation between the various non-small-cell lung cancer subtypes is crucial for providing an effective treatment to the patient. For this purpose, machine learning techniques have been used in recent years over the available biological data from patients. However, in most cases this problem has been treated using a single-modality approach, not exploring the potential of the multi-scale and multi-omic nature of cancer data for the classification. In this work, we study the fusion of five multi-scale and multi-omic modalities (RNA-Seq, miRNA-Seq, whole-slide imaging, copy number variation, and DNA methylation) by using a late fusion strategy and machine learning techniques. We train an independent machine learning model for each modality and we explore the interactions and gains that can be obtained by fusing their outputs in an increasing manner, by using a novel optimization approach to compute the parameters of the late fusion. The final classification model, using all modalities, obtains an F1 score of 96.81 +/- 1.07, an AUC of 0.993 +/- 0.004, and an AUPRC of 0.980 +/- 0.016, improving those results that each independent model obtains and those presented in the literature for this problem. These obtained results show that leveraging the multi-scale and multi-omic nature of cancer data can enhance the performance of single-modality clinical decision support systems in personalized medicine, consequently improving the diagnosis of the patient.